

**IPO : Goldline Pharmaceutical Limited****May 2026****Snapshot**

Goldline Pharmaceutical Limited is a pharmaceutical company engaged in the distribution and trading of pharmaceutical products and healthcare solutions across India. Incorporated in 2004 and headquartered in Nagpur, Maharashtra, the company focuses on supplying a wide range of medicines and healthcare products through its established distribution network. Goldline Pharmaceutical aims to strengthen its market presence by improving operational efficiency, expanding its product portfolio, and enhancing customer relationships. The company is launching its SME IPO on the BSE platform to raise funds for business growth and working capital requirements. With experienced promoters and industry knowledge, the company seeks to capitalize on the growing demand in India's pharmaceutical sector.

**Company Vision**

Goldline Pharmaceutical Limited envisions becoming a trusted and recognized name in the Indian pharmaceutical industry by delivering quality healthcare products and ensuring reliable distribution services across markets. The company aims to expand its reach through stronger customer relationships, improved operational capabilities, and a diversified product portfolio. Goldline Pharmaceutical also seeks to leverage industry growth opportunities by enhancing efficiency and strengthening its market presence in both existing and new regions. Through sustainable growth and ethical business practices, the company aspires to create long-term value for stakeholders.

**Growth Prospects**

Goldline Pharmaceutical Limited has promising growth prospects driven by the increasing demand for pharmaceutical and healthcare products in India. The company plans to utilize the IPO proceeds to strengthen working capital, improve operational efficiency, and expand its distribution network. Rising healthcare awareness, growing pharmaceutical consumption, and expansion into new markets can support long-term business growth. With experienced promoters, an established customer base, and industry expertise, the company is well-positioned to benefit from the expanding Indian pharma sector. Additionally, opportunities in generic medicines, healthcare distribution, and increasing access to medical services across India.

Opening Date	Tuesday, May 12, 2026
Closing Date	Thursday, May 14, 2026
Price Band	Rs. 41 to Rs. 43 per share
Bid Lot	3000 Shares
Face Value	Rs. 10 per share
Issue Size	27,00,000 shares (aggregating up to Rs. 12 Cr)
Reserved for Market Maker	1,38,000 shares (aggregating up to Rs. 0.5 Cr)
Fresh Issue	25,62,000 shares (aggregating up to Rs. 11 Cr)
Registrar	Bigshare Services Pvt.Ltd.

**Key Financials**

Amount in cr.	Dec-2025	FY2025	FY2024	FY2023
Assets	27.40	26.28	22.93	19.39
Total Income	21.41	28.06	23.57	19.85
Profit After Tax	2.22	2.83	1.81	0.26
EBITDA	4.16	5.83	4.30	2.19
NET Worth	12.36	10.35	7.86	5.89
Reserves and Surplus	3.65	1.65	3.76	2.08
Total Borrowing	9.47	11.03	11.13	10.83

**Risk Assessment**

Goldline Pharmaceutical Limited faces several business risks that could impact its financial performance and growth. The company operates in a highly competitive pharmaceutical industry where pricing pressure, changing regulations, and dependence on suppliers may affect profitability. Any disruption in the supply chain, increase in working capital requirements, or failure to maintain product quality standards could negatively impact operations. The business is also exposed to risks related to government healthcare policies, compliance requirements, and market competition from larger pharmaceutical companies. Additionally, fluctuations in demand, customer concentration, and economic slowdowns may influence revenue generation and overall business stability in the future.